1. Combination of a CD26 Inhibitor, G-CSF, and Short-term Immunosuppressants Modulates Allotransplant Survival and Immunoregulation in a Rodent Hindlimb Allotransplant Model
- Author
-
Chien-Chang Chen, Yur-Ren Kuo, Jiin-Haur Chuang, Y Wang, Rong-Fu Chen, and Yun-Ting Li
- Subjects
CD4-Positive T-Lymphocytes ,Graft Rejection ,Male ,Time Factors ,Stromal cell ,Dipeptidyl Peptidase 4 ,medicine.medical_treatment ,Hindlimb ,030230 surgery ,Granulocyte ,Pharmacology ,Drug Administration Schedule ,Vascularized Composite Allotransplantation ,Transforming Growth Factor beta1 ,03 medical and health sciences ,0302 clinical medicine ,Rats, Inbred BN ,Granulocyte Colony-Stimulating Factor ,Animals ,Medicine ,IL-2 receptor ,Antilymphocyte Serum ,Dipeptidyl-Peptidase IV Inhibitors ,Transplantation ,business.industry ,Graft Survival ,FOXP3 ,Mixed lymphocyte reaction ,Chemokine CXCL12 ,Interleukin-10 ,medicine.anatomical_structure ,Rats, Inbred Lew ,Cyclosporine ,030211 gastroenterology & hepatology ,Composite Tissue Allografts ,business ,Immunosuppressive Agents ,Allotransplantation - Abstract
BACKGROUND Recent studies have demonstrated that inhibition of CD26 potentiates stromal cell-derived factor-1α (SDF-1α), promotes tissue regeneration, and suppresses the rejection of organ transplants. This study investigated whether the combination of a CD26 inhibitor (CD26i) with granulocyte colony-stimulating factor (G-CSF) and short-term immunosuppressants modulates vascularized composite tissue allotransplant survival in a rodent orthotopic hindlimb allotransplant model. METHODS The hindlimb allotransplantation from Brown-Norway to Lewis rats was divided into 4 groups. Group 1 (controls) did not receive any treatment. Group 2 was treated with short-term antilymphocyte serum (ALS) and cyclosporine-A (CsA). Group 3 was administrated CD26i and G-CSF. Group 4 received a combination of CD26i/G-CSF/ALS/CsA. Each subgroup comprised 10 rats. Peripheral blood and sampling of transplanted tissues were collected for immunological and histological analysis. RESULTS The results revealed that allotransplant survival was found to be significantly prolonged in group 4 with CD26i/G-CSF/ALS/CsA treatment compared with those in the other groups. The interleukin-10 and transforming growth factor-βl levels, the percentage of CD4+/CD25+/FoxP3+ T cells, as well as the levels of SDF-1α expressions were significantly increased in group 4 compared with those in the other groups. Group 4 revealed a statistical increase in the percentage of donor cells (RT1n) expression in the recipient peripheral blood, and the mixed lymphocyte reaction showed hyporesponsiveness of the T cells to donor alloantigens. CONCLUSION The combination of CD26i/G-CSF and short-term immunosuppressants prolongs allotransplant survival by inducing immunoregulatory effects and enhancing the percentage of SDF-1α expression. This immunomodulatory approach has great potential as a strategy to increase vascularized composite allotransplantation survival.
- Published
- 2021